Cohance Lifesciences Receives USFDA EIR with VAI Status for Pashamylaram Facility
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 07 Nov 2026, 4:41 pm
Cohance Lifesciences Receives USFDA EIR with VAI Status for Pashamylaram Facility Cohance Lifesciences Limited has received the Establishment Inspection Report (EIR) from the USFDA for its manufacturing facility located at Pashamylaram, Hyderabad (FEI No. 1000623515). The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI), successfully concluding the inspection previously communicated on 5th Aug'26.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Audio link for the conference call 路 07 Nov 2026
